04-Sep-15 Korean medical companies will speed up their entry into China, having secured a bridgehead into the telemedicine market by inking agreements with Chinese partners. Other agreements will allow Korea to export more drugs and biotech to China. These developments will help Korea become one of the top seven healthcare powers within five years. [image: Business Korea]

02-Sep-15 China's economic downturn plus other factors, including overcapacity and tightening regulations, mean the next two to three years could be challenging for the foreign chemical and pharmaceutical companies located there. [image: Want China Times]

23-Aug-15 Emerging-market sales for the big pharmaceuticals firms increased by about 5.5% year over year in the second quarter, well below the 9% average of the prior four quarters. Macroeconomic pressures are increasing. Weaker currencies hurt sales, a factor put into clear focus by China’s devaluation of the yuan. [image: Nai 500]

26-Aug-15 China is aiming to control “wildly” growing stem cell therapy, issuing its first regulation covering the largely controversial medical procedure. “Only eligible hospitals can work with stem cells in clinical trials for research and there must not be fees or advertising,” said the National Health and Family Planning Commission. [image: Liu Haifeng / Xinhua Press / Corbis]

19-Aug-15 A new guideline allows foreign drugs to undergo clinical trials in their home country and in China at the same pace, speeding up approval procedures for new drugs that are badly needed in China. Clinical trials of new foreign drugs in China normally lag behind those in the home country. [image: Alamy / Daily Mail]